Moderna Inc. Chief Financial Officer Jorge Gomez departed a day after taking charge, the vaccine maker said on May 11, following his former employer disclosing an internal probe related to financial reporting.

BioNTech’s first-quarter 2022 sales and earnings more than tripled due to demand for the COVID-19 vaccine the company developed with Pfizer, but the German biotech firm is still forecasting a full-year decline in vaccine sales.

Moderna Inc. on May 4 forecast higher vaccine sales for the second half of 2022 than in the first six months of the year, as the company expects the virus that causes COVID-19 to follow a more seasonal pattern requiring booster shots in the fall.

AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.

AstraZeneca topped off a very busy week with the company’s first-quarter 2022 financial report, citing a total of $11.39 billion in revenue, a whopping increase of 60 percent. That performance was driven by the acquisition of Alexion and several contracts for Vaxzevria, AstraZeneca’s COVID-19 vaccine developed with the University of Oxford.

Sanofi

Sanofi reported a series of first-quarter 2022 wins, driven mostly by the success of consumer healthcare (CHC) and the company’s blockbuster Dupixent.

Merck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.

Eli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.

GlaxoSmithKline

GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.

Roche’s first-quarter 2022 sales rose 10 percent on strong U.S. demand for rapid COVID-19 antigen tests and specialty drugs but the Swiss drugmaker reaffirmed that a drop in pandemic-related demand would put the brakes on growth.